Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Merck halts Phase 3 Lynparza for futility

By Brian Buntz | July 18, 2022

Merck in the Drug Discovery & Development Pharma 50Merck (NYSE:MRK) has announced that it will stop the Phase 3 LYNK-003 trial focused on Lynparza (olaparib) with or without bevacizumab for patients with unresectable or metastatic colorectal cancer.

Two experimental arms in the trial, one focused on Lynparza as monotherapy or in combination with the immunotherapy drug bevacizumab, will be suspended.

The primary endpoint of the trial was progression-free survival.

The study focused on patients without progression after first-line therapy.

Merck made the decision after receiving feedback from an independent Data Monitoring Committee (DMC) following review from an interim analysis.

The PARP inhibitor Lynparza was first developed by KuDOS Pharmaceuticals and the University of Pennsylvania.

AstraZeneca acquired KuDOS Pharmaceuticals in 2005.

In 2021, the drug jointly earned AstraZeneca and Merck $3.7 billion.

The two companies continue to develop Lynparza for a variety of oncology indications, including metastatic breast, prostate, ovarian and pancreatic cancer.

The drug first won FDA approval for maintenance treatment of ovarian cancer in 2017.

MRK shares dipped 2.76% to $92.34 while AZN shares were up 0.63% to £11,200.00.


Filed Under: clinical trials, Drug Discovery, Oncology
Tagged With: AstraZeneca, Lynparza, Merck
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

AstraZeneca/Daiichi-Sankyo
FDA approves Enhertu for HER2-low breast cancer
ChemoCentryx/Amgen
Amgen to pay almost $4B for ChemoCentryx
Olema Oncology
Olema Oncology’s OP-1250 could be a game-changing breast cancer drug
Amazon/Fred Hutch
Amazon partners with Fred Hutchinson Cancer on cancer vaccine trial 

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50